GSK adds to COPD drug push with Empirico deal

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
pharmaphorum

GSK strikes again, adding COPD candidate in $745m deal

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
Fierce Biotech

GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Lower eosinophil count linked to mortality in patients with acute COPD exacerbation in ICU

For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...

UK industry body finds AstraZeneca in breach of code over Symbicort marketing

AstraZeneca breached the UK pharmaceutical industry's code of practice after a website claim incorrectly stated that all ...

COPD Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regen…

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...
The American Journal of Managed Care

Preventing COPD Readmissions With Dedicated RTs: Megan Dulohery Scrodin, MD

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
Medical Dialogues

COPD Patients with Respiratory Failure Face Higher and Earlier CV Risks: Study Finds

Italy: A new 15-year analysis has revealed that patients with chronic obstructive pulmonary disease (COPD) who also have ...
Pulmonology Advisor

Brensocatib Beneficial in Bronchiectasis Regardless of Patient’s COPD Status

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...

Asthma vs. COPD: Why early differentiation matters, according to pulmonologist

Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...

Diwali 2025: How asthma and COPD patients can protect their lungs from smog

As pollution peaks during Diwali, doctors share essential tips to help people with asthma, COPD, or bronchitis stay safe from ...

Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre

Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:VRNA).